There are updates to the biotech review process in the phase one trade deal with China. American Seed Trade Association President and CEO Andy LaVigne says the process provides more clarity moving forward. “The current process is a bit cloudy and not consistent. It often takes on average about seven-to-eight years for biotech approval from China,” explains LaVigne. “They have now committed to make it an average of two years for products going through the process.” LaVigne says respect and understanding of intellectual property is a concern. Enforcement could be the challenge.
